<DOC>
	<DOCNO>NCT02030860</DOCNO>
	<brief_summary>This study randomize pilot/pharmacodynamic/genomic study neoadjuvant paricalcitol target microenvironment resectable pancreatic cancer determine effect target vitamin D metabolic program tumor patient treat one cycle gemcitabine/abraxane without paricalcitol prior surgery resectable pancreatic cancer assessment cellular imaging marker .</brief_summary>
	<brief_title>A Randomized Pilot/Pharmacodynamic/Genomic Study Neoadjuvant Paricalcitol Target Microenvironment Resectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Inclusion Criteria Previously untreated , apparently resectable , adenocarcinoma pancreas registration . Age great equal 18 year ECOG performance status 02 . Standard laboratory criterion hematologic , biochemical , urinary index within range , opinion physician , clinically support enrollment patient trial . Note : subject must : Creatinine &lt; 2xULN , Transaminases &lt; 3xULN , Neutrophils &gt; 1.5x109/L , Platelets &gt; 100,000/mm3 Ability provide write informed consent Exclusion Criteria Patients hypercalcemia ( blood level great 11.5 mg/dL ; patient kidney disease , blood calcium level must 9.5 mg/dL low start paricalcitol ) . Patients currently pregnant , plan become pregnant , breastfeed . Patients , opinion physician , would clinically appropriate receipt therapy regimen associate participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>